ArticleFrontiers in surgery2026
Traditional Chinese medicine fumigation combined with Musk hemorrhoid suppository for wound healing and inflammation control in patients with mixed hemorrhoids after Milligan-Morgan hemorrhoidectomy.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy, safety, and underlying mechanism of traditional Chinese medicine (TCM) fumigation combined with Musk hemorrhoid suppository for postoperative recovery in patients with mixed hemorrhoids undergoing Milligan-Morgan Hemorrhoidectomy (MMH). Methods: A prospective, stratified randomized controlled study enrolled 160 patients, who were stratified by hemorrhoid grade and randomized into four groups (40 cases each): combined (TCM fumigation + Musk suppository), fumigation alone, suppository alone, and control (1:5,000 potassium permanganate sitz bath). An internal validation cohort (40 cases, 25% of the main trial size) was included to confirm result consistency. The primary endpoint was complete wound epithelialization rate at postoperative day (POD) 14, with secondary endpoints including wound healing time, total effective rate at 4 weeks postoperatively, anal function, serum inflammatory factors (IL-6, TNF-α, CRP) and tissue NF-κB p65 protein, complication incidence, and quality of life (GQOL-30). Statistical analyses used Bonferroni correction for multiple comparisons to control Type I error ( Results: All groups had balanced baseline characteristics (all Conclusion: The combined TCM regimen safely accelerates postoperative recovery after MMH, reduces inflammation and complications, and improves patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.